[Federal Register Volume 80, Number 234 (Monday, December 7, 2015)]
[Notices]
[Pages 76026-76027]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-30752]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health (NIH)
Prospective Grant of Start-Up Exclusive Evaluation Option License
Agreement: Development and Commercialization of Aza-Epoxy Guaiane
Derivatives for Treatment of Renal Cancer
AGENCY: National Institutes of Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Cancer Institute (NCI), National Institutes
of Health, Department of Health and Human Services, is contemplating
the grant of a Start-Up Exclusive Evaluation Option License Agreement
to ElexiMed LLC, a company having a place of business at 5003 Green
Mountain Circle, Suite 4, Columbia, MD 21044, USA, to practice the
inventions embodied in the following patent applications.
Intellectual Property--PCT Patent Application No. PCT/US2015/
014601, entitled ``Aza-Englerin Analogues--Novel Natural Product-Based
Nitrogen-Containing Anti-Cancer Agents'' filed February 5, 2015 (HHS
Ref. No.: E-090-2014/2-PCT-01); US Provisional Patent
[[Page 76027]]
Application No. 62/018,381, entitled ``Aza-epoxy-guaiane derivatives
and treatment of cancer'' filed June 27, 2014 (HHS Ref. No. E-090-2014/
1-US-01); and US Provisional Patent Application No. 61/936,285,
entitled ``Aza-englerin analogues and use in cancer therapy'' filed
February 5, 2014 (HHS Ref. No. E-090-2014/0-US-01).
The patent rights in these inventions have been assigned to the
Government of the United States of America and the University of
Hawaii.
The territory of the prospective Start-Up Exclusive Evaluation
Option License Agreement may be worldwide, and the field of use may be
limited to ``Development and commercialization of aza-epoxy guaiane
derivatives for treatment of renal cancer.''
Upon the expiration or termination of the Start-up Exclusive
Evaluation Option License Agreement, ElexiMed LLC will have the
exclusive right to execute a Start-Up Exclusive Patent License
Agreement which will supersede and replace the Start-up Exclusive
Evaluation Option License Agreement, with no greater field of use and
territory than granted in the Start-up Exclusive Evaluation Option
License Agreement.
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center on or before
December 22, 2015 will be considered.
ADDRESSES: Requests for copies of the patent application(s), inquiries,
comments, and other materials relating to the contemplated Start-Up
Exclusive Evaluation Option License Agreement should be directed to:
Rose Freel, Ph.D., Licensing and Patenting Manager, Technology Transfer
Center, National Cancer Institute, Riverside 5, Suite 400, 8490
Progress Drive, Frederick, MD 21702; telephone: 301-624-1257;
Facsimile: 301-631-3027; Email: [email protected]. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: This technology describes aza-englerins,
synthetic analogues of the natural product Englerin A which displays
potent and selective anti-cancer properties in several cancer cell
lines. The aza-englerins were developed as novel cancer therapeutics
and show significant bioavailability after oral administration in mice.
The prospective Start-Up Exclusive Evaluation Option License
Agreement is being considered under the small business initiative
launched on October 1, 2011 and will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective
Start-Up Exclusive Evaluation Option License Agreement and a subsequent
Start-Up Exclusive Patent License Agreement may be granted unless the
NCI receives written evidence and argument, within fifteen (15) days
from the date of this published notice, that establishes that the grant
of the contemplated Start-Up Exclusive Evaluation Option License
Agreement would not be consistent with the requirements of 35 U.S.C.
209 and 37 CFR part 404.7.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Start-Up Exclusive Evaluation Option
License Agreement. Comments and objections submitted to this notice
will not be made available for public inspection and, to the extent
permitted by law, will not be released under the Freedom of Information
Act, 5 U.S.C. 552.
Dated: December 2, 2015.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2015-30752 Filed 12-4-15; 8:45 am]
BILLING CODE 4140-01-P